Purdue Pharma—U.S. Food and Drug Administration (FDA)

Purdue Pharma—U.S. Food and Drug Administration (FDA) describes a consequential relationship between a drug manufacturer and the regulator responsible for approving and overseeing its products. OxyContin received FDA approval in 1995, despite information in its application about how crushing the tablets could release the drug rapidly and how much oxycodone could be recovered for injection. The later black-box warning and unsuccessful efforts to restrict or recall the drug made the relationship a continuing dispute over what the FDA knew, what it did, and how far corporate interests shaped the terms of public protection.

Approval and the evidence in the application

Purdue Frederick, the family-owned company that developed OxyContin, had built a pain-relief business around MS Contin, a morphine-derived medication introduced in 1984. As MS Contin’s patent approached expiration, Purdue developed OxyContin as a reformulation of oxycodone and intended to market it beyond hospice and end-of-life care. The FDA approved the drug in late 1995, opening the way for its use in a much broader pain market.

The approval record later became central to criticism of both Purdue and the FDA. Curtis Wright, the agency’s lead examiner, signed off on a New Drug Application filed in 1995. Its review described that crushing the tablets could turn their intended controlled release into immediate release. It also recorded withdrawal symptoms in several clinical-trial patients and stated that 68 percent of the oxycodone in one crushed tablet could be recovered when liquefied and injected. Those particulars sit uneasily beside Purdue’s later claim that it had not known of OxyContin’s abuse problems until February 2000.

Wright’s approval summary also urged caution in the drug’s promotional materials, advising that competitive promotion be limited. The account contrasts that advice with what followed: Purdue promoted OxyContin beyond its earlier end-of-life market. Wright went on to work as a consultant for Purdue Pharma two years after approving the drug. The sequence is evidence of a later professional connection, but it does not by itself establish that the consulting role caused, or altered, the approval decision.

Warning and the gap between oversight and practice

In July 2001, the FDA announced that it had worked with Purdue to add a black-box warning, the strongest category of prescription-drug caution. The stated purpose was to help prevent inappropriate prescribing, misuse, and diversion. This was a significant regulatory step, but the warning’s meaning was contested almost immediately. A Purdue spokesperson characterized it as largely a matter of graphic design and emphasized that patients using the drug legitimately did not experience the high sought by people who crushed, snorted, or injected it. Company executives repeatedly framed restrictions as a threat to legitimate patients’ access.

Other evidence in the account complicates that public defense. A former Purdue representative recalled attending a company seminar intended to teach sales staff about diversion and abuse, while also describing how high-dose prescribing could bring sales representatives substantial quarterly bonuses. The former representative’s account suggests a gap between the company’s stated education and the incentives surrounding its sales work. It does not show that the FDA directed those incentives; rather, it raises the question of whether a warning could meaningfully constrain practices that the manufacturer had commercial reasons to sustain.

The FDA’s decisions also remained disputed after the black-box warning. In 2004, the agency chose not to restrict OxyContin to severe pain, a change that Barbara Van Rooyan believed might have reduced addiction without preventing use by terminally ill patients. She supported OxyContin for terminal and acute pain in appropriate circumstances but opposed its use for chronic, noncancer pain before other treatments had been explored. Her son Patrick Van Rooyan had died the year before. Her criticism therefore focused not on eliminating all access to the drug, but on the breadth of the indication and the FDA’s repeated opportunities to respond to risk.

Petitions and efforts to force action

The challenge moved from public criticism into a formal recall campaign. Art Van Zee had assembled extensive information about OxyContin and previously gathered ten thousand signatures, but his petition was never formally submitted to the FDA because his effort lacked the time, staff, and energy to complete the process. Barbara Van Rooyan, a researcher and professor, took up the filing with help from her physician husband and incorporated Van Zee’s data into her submission.

On February 1, 2005, Van Rooyan filed a petition asking the FDA to recall OxyContin temporarily until it could be reformulated to resist abuse and relabeled for severe pain only. She later testified alongside Van Zee at FDA hearings and protested outside a Purdue-funded continuing-medical-education seminar. She remembered the agency’s recall form as long and burdensome. The account also notes that a separate petition, filed by the Connecticut attorney general in 2004, sought stronger warning labels about frequent prescribing; it remained stalled and was rejected in 2008. Van Rooyan continued to seek an answer to her own petition, but the account records her waiting rather than a resolution.

The campaign exposed how much of the burden of pursuing regulatory action fell to individuals and families. Van Zee’s earlier effort had gathered signatures but could not be completed; Van Rooyan’s research and persistence carried the evidence into a formal filing. FDA staff became familiar with her repeated calls. Her petition did not simply oppose a medicine: it demanded narrower labeling and an abuse-resistant formulation, arguing that protection from addiction and access for patients in severe or terminal pain did not have to be treated as mutually exclusive.

Broader questions of influence and accountability

Later reporting widened the scrutiny from OxyContin’s specific approval and warnings to the institutional setting in which drug regulation occurred. In 2013, a Milwaukee Journal Sentinel investigation revealed that FDA regulators and pharmaceutical executives had held private meetings at expensive hotels at least annually since 2002 through an industry-funded nonprofit. Those meetings led to the development of enriched enrollment, a practice that could exclude study participants who did not respond well to a drug, making trial results more favorable to approval. The account presents this as a broader regulatory concern; it does not establish that Purdue attended those meetings or that they determined OxyContin’s approval.

The same reporter documented that the American Pain Society and the American Academy of Pain Medicine advocated wider opioid use for long-term chronic pain while receiving millions from companies that manufactured opioids. The resulting 2012 Senate investigation targeted the American Pain Foundation and Purdue, among other organizations and pharmaceutical companies. Its findings were kept in the Senate Finance Committee’s office and remained unavailable despite calls for disclosure. That outcome left public questions about industry relationships without a corresponding public record of the investigation’s conclusions.

Taken together, the episodes portray a relationship marked by both formal regulation and persistent challenges to its adequacy. The FDA approved OxyContin, later collaborated with Purdue on a black-box warning, and declined a severe-pain-only restriction; families and advocates disputed those choices and sought stronger action. The documented approval review, the company’s public framing of the warning, the delayed or unsuccessful petitions, and the wider scrutiny of industry ties provide distinct grounds for concern. They do not prove that every FDA decision was dictated by Purdue, but they show why the relationship became a central question of accountability: the regulator’s safeguards and the manufacturer’s assurances were repeatedly measured against evidence of risk and the consequences experienced by patients and families.